Comparative Pharmacology
Head-to-head clinical analysis: EFAVIRENZ versus PIFELTRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EFAVIRENZ versus PIFELTRO.
EFAVIRENZ vs PIFELTRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to and inhibits HIV-1 reverse transcriptase, blocking RNA-dependent and DNA-dependent DNA polymerase activities.
Selective allosteric inhibitor of HIV-1 capsid protein, interfering with multiple steps of the viral life cycle including capsid assembly, nuclear import, and virion maturation.
600 mg orally once daily, taken on an empty stomach, preferably at bedtime.
200 mg orally once daily, taken with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 52-76 hours after single doses and 40-55 hours after multiple doses. The long half-life supports once-daily dosing and allows for steady-state concentrations within 6-10 days.
Clinical Note
moderateEfavirenz + Tranilast
"The serum concentration of Tranilast can be decreased when it is combined with Efavirenz."
Clinical Note
moderateEfavirenz + Tolfenamic acid
"The serum concentration of Tolfenamic acid can be decreased when it is combined with Efavirenz."
Clinical Note
moderateEfavirenz + Nimesulide
"The serum concentration of Nimesulide can be decreased when it is combined with Efavirenz."
Clinical Note
moderateEfavirenz + Risedronic acid
12-13 hours in healthy subjects; clinically, supports once-daily dosing.
Efavirenz is primarily metabolized by the liver via CYP2B6 and CYP3A4/5. Renal excretion of unchanged drug is minimal (<1%). Approximately 14-34% of a dose is recovered in urine as metabolites, and 16-61% in feces as unchanged drug or metabolites.
Primarily hepatic metabolism with subsequent biliary/fecal elimination. 86% of a single oral dose recovered in feces (mostly as metabolites) and <1% unchanged in urine.
Category D/X
Category C
NNRTI
NNRTI
"The serum concentration of Risedronic acid can be decreased when it is combined with Efavirenz."